The company's device, dubbed Ecore, helps to modernise embolisation procedures - a minimally invasive procedure that blocks blood vessels to treat a variety of conditions such as bleeding and tumours.
The device is shaped like an umbrella and enters blood vessels deep within the body to form an occlusive barrier.
Ecore allows doctors to restrict blood flow in a targeted segment of the veins or arteries while still while allowing ancillary tools like catheters to pass through. This will complement liquid and microparticle embolisation.
Exposure to X-ray radiation is also reduced for both patient and practitioner, and lowers the risk of human errors like inadvertently blocking blood flow to healthy adjacent organs.
The device can be used in oncology, treatment of benign tumours and haemorrhages - and will make it safer and cheaper to treat these ailments. It is initially targeting treatments used to enable liver cancer patients to safely receive curative surgery.
The funding round was co-led by Elkstone and Atlantic Bridge, with participation from Enterprise Ireland and Furthr VC. The funding will be used to accelerate product development and market access.
Speaking on the announcement CEO and Co-founder of LaNua Medical Tom Fitzmaurice said, “We are delighted to complete this €6 million seed round bringing on board sophisticated and experienced Medical Technology investors in Ireland and the United States. It will enable our team to hire additional skilled resources, develop a range of devices to meet the growing demands of embolization in the Interventional Radiology medical community and gain entry into our first market in the United States.”
